{
}
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner, driven by positive trends in weight loss drug prescriptions, particularly for GLP-1 appetite suppressants. Analyst Jo Walton noted that Eli Lilly's Zepbound is currently leading the market.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner, driven by positive trends in weight loss drugs, particularly GLP-1 appetite suppressants. Analyst Jo Walton noted that while all appetite suppressants are experiencing growth, Eli Lilly's Zepbound is leading the market.
Raiffeisen Research has added Vonovia to its Top Picks list, citing its attractive valuation with a price-to-book ratio of around 0.8 amid rising yields. The demand for rentals in Germany is expected to remain strong due to affordability issues and a shortage of new buildings, while recent interest rate cuts are lowering refinancing costs. The updated Top Picks include notable companies such as 3M, Amazon, and Microsoft, alongside Vonovia.
Barclays has reduced its Q1 2025 estimates for Novo Nordisk, citing lower-than-expected prescription volumes for Wegovy and Ozempic in the U.S. The bank anticipates sales and operating profit to fall 2% and 3% below Bloomberg consensus, projecting 19% constant-currency sales growth for the full year, below Novo's guidance range.Despite recent positive developments, including Wegovy's removal from the FDA's drug shortage list, prescription trends have remained flat. Analysts are cautious about potential guidance cuts depending on volume recovery in the latter part of the year, while Barclays maintains an Overweight rating and a DKK 900 price target, confident in the long-term prospects of the GLP-1 franchise.
Barclays has downgraded Novo Nordisk's Q1 forecast due to slower-than-expected growth in US prescriptions for its weight-loss drugs, Wegovy and Ozempic. Projected sales and operating profit are now about 2% and 3% below Bloomberg's consensus, respectively. Despite these challenges, Barclays maintains an overweight rating and a price target of 900 Danish kroner, reflecting confidence in Novo's long-term growth potential.
Barclays has reduced its Q1 2025 estimates for Novo Nordisk, citing lower-than-expected prescription volumes for Wegovy and Ozempic in the U.S. Sales and operating profit are now projected to be 2% and 3% below Bloomberg consensus, respectively. Despite positive developments, prescription trends remain flat, raising concerns about future volume recovery as the company intensifies efforts against unauthorized compounded semaglutide. Barclays maintains an Overweight rating and a DKK 900 price target, confident in the long-term prospects of the GLP-1 franchise.
Barclays has revised its Q1 projections for Novo Nordisk, citing weaker prescription growth for Wegovy and Ozempic. The company focuses on pharmaceutical products, with 93.6% of net sales from diabetes and obesity treatments, while rare disease treatments account for 6.4%. Geographically, sales are led by the United States at 57.6%, followed by Europe/Middle East/Africa at 20.8%.
UBS has maintained a "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton highlighted current prescription trends in the U.S. for the GLP-1 active ingredient, known for its appetite-suppressing effects.
UBS has rated Novo Nordisk as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and does not replace tailored expert investment advice. No liability for the accuracy or completeness of the information is assumed.
Novo Nordisk's shares have dropped over 20% this year, primarily due to disappointing results for its weight loss drug CagriSema and concerns about Wegovy's market performance against Eli Lilly's Zepbound. Despite this, UBS maintains a "buy" rating with a target price of 750 DKK, suggesting a potential 56% upside. Wall Street remains divided, with half of analysts recommending a buy and the other half advising to hold, but no sell ratings are present.
Novo Nordisk A/S
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for novo nordisk with target price of 750 kroner
20:14 04.04.2025
ubs maintains buy rating for novo nordisk with target price of 750 kroner
17:08 04.04.2025
Raiffeisen Research Adds Vonovia to Top Picks Amid Attractive Valuation
The Walt Disney Co
Deutsche Post AG
Qualcomm Inc
Palfinger AG
Heineken N.V.
Nestle SA
Pfizer Inc.
Zalando SE
VONOVIA
Novo Nordisk A/S
AUT
DEU
Show more
16:53 01.04.2025
barclays lowers novo nordisk estimates on weak us drug volumes
16:12 01.04.2025
barclays lowers novo nordisk q1 forecast amid prescription growth challenges
16:03 01.04.2025
Barclays lowers Novo Nordisk estimates amid weak Wegovy and Ozempic sales
15:42 01.04.2025
barclays lowers novo nordisk first quarter forecasts on prescription growth decline
15:19 01.04.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
22:34 31.03.2025
ubs rates novo nordisk as buy amid investment considerations and risks
20:17 31.03.2025
ubs predicts over 50 percent recovery for novo nordisk shares
19:30 28.03.2025
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
Stock Market Updates
Government Economic Policies
Industry Mergers & Acquisitions
Energy Sector Developments
Workplace Trends
Funding Rounds & Investments
CEO Changes
AI Applications
Private Equity Deals
Emerging Startups
Fintech Startups
AI Innovations
Global Financial Events
Central Bank Actions
Countries:
Companies:
Apple Inc.
Google Inc.
Tesla, Inc.
Amazon.com, Inc.
Microsoft Corporation
Tesmec S.p.A.
Alphabet Inc.
OpenAI ERC USD
Walmart Inc.
SWIGGY LIMITED
TENCENT
NVIDIA Corporation
Foxconn Technology Co., Ltd.
Hollywood Bowl Group PLC
NASDAQ Composite
Wise plc
Mastercard Inc
Bose Corporation
Mistral 1
Fast Retailing Co., Ltd.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
British Pound Sterling
Japanese Yen
United Arab Emirates Dirham
Vietnamese Đồng
South Korean Won
New Zealand Dollar
Saudi Riyal
Thai Baht
Australian Dollar
Indonesian Rupiah
Singapore Dollar
Omani Rial
Bahraini Dinar
Qatari Riyal
Algerian Dinar
Egyptian Pound
People: